(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 June 2020 (04.06.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/112514 A1

(51) International Patent Classification:
A61K 31/445 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2019/062718

(22) International Filing Date:
22 November 2019 (22.11.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/773,367 30 November 2018 (30.11.2018) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46206-6288 (US).

(72) Inventors: **DOWLESS, Michele Suzanne**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **GONG, Xueqian**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **STANCATO, Louis Frank**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agent: **MYERS, James B.** et al.; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: AN AURORA A KINASE INHIBITOR FOR USE IN THE TREATMENT OF NEUROBLASTOMA



(I)

(57) Abstract: The present invention provides an inhibitor of Aurora A kinase, Formula (I) illustrated below, or pharmaceutically acceptable salt thereof, for use in treating neuroblastoma.

WO 2020/112514 A1

An Aurora A Kinase Inhibitor for Use in the Treatment of Neuroblastoma

The present invention relates to the use of an Aurora A kinase inhibitor, and salts thereof, for the treatment of neuroblastoma.

Neuroblastoma is one of the most common solid tumors in children, and more than 650 neuroblastoma cases are diagnosed each year in North America. Neuroblastoma can be subdivided into two defined patient subsets, referred to generally as low risk and high risk. Low risk neuroblastoma is usually found in children younger than 18 months of age with limited disease burden resulting in a favorable prognosis. However, high-risk neuroblastoma generally occurs in children older than 18 months, frequently metastatic in bone tissue, resulting in poor prognosis. Although advances in multimodal treatment strategies have led to improved outcomes for neuroblastoma patients, survival rates for the high-risk category patients remain poor with less than 50% survival five years after diagnosis.

High-risk neuroblastoma is associated with the MYCN gene which encodes the N-myc proto-oncogene protein (N-MYC). Although incompletely understood, N-MYC and Aurora A Kinase appear to interact, and Aurora A kinase expression and amplification are thought to stabilize N-MYC and/or slow its degradation, which in turn would cause an increase in N-MYC levels. Michaelis, M, et al., "Aurora Kinases as Targets in Drug–Resistant Neuroblastoma Cells", PLOS One, 2014, **9**(9) e108758.

Aurora A kinase inhibitors are known in the art (see, for example, PCT Patent Application Publication, WO2016/077191, which discloses the compound of Formula I (see below). Use of certain Aurora kinase inhibitors, including an Aurora A selective inhibitor, alisertib, and a pan Aurora inhibitor, tozasertib, have been associated with unacceptably high levels of neutropenia and other toxic effects.

A need exists for novel approaches and medications to treat neuroblastoma, in particular, high-risk neuroblastoma. In addition, there is a need to provide methods of inhibiting Aurora kinases, in particular Aurora A kinase, and decreasing the expression and/or activity of N-MYC. The present invention addresses these needs and provides a method of treating neuroblastoma.

In one form, the present invention provides a method for treating neuroblastoma in a patient in need of treatment. Preferably the present invention provides a method for treating high neuroblastoma in a patient in need of treatment. The method comprises

administering to the patient an effective amount of a compound which is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid, illustrated below as Formula I, or a pharmaceutically acceptable salt of the compound of Formula I. In one embodiment, the compound of Formula I is provided as a free acid. In another embodiment, the compound of Formula I is provided as a base addition salt. In one preferred embodiment, the compound of Formula I is provided as a 2-methylpropan-2-ammonium salt (also known as an erbumine salt or a *tert*-butylamine salt) that is ((2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid : 2-methyl-2-propanamine (1:1)). In another embodiment, the compound of Formula I is provided as an ammonium salt ((2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid : amine (1:1) salt).



Formula I

In another form, the present invention provides a pharmaceutical composition comprising the compound of Formula I, or a pharmaceutically acceptable salt thereof, and one or more of a pharmaceutically acceptable: carrier, diluent, or excipient for use in treating neuroblastoma, preferably for treating high risk neuroblastoma. In one embodiment, the composition comprises a compound of Formula I, which is free acid. In another embodiment, the composition comprises a compound of Formula I as a base addition salt, preferably, a 2-methylpropan-2-ammonium salt or an ammonium salt, more preferable a methylpropan-2-ammonium salt.

The present invention provides the compound of Formula I, or a pharmaceutically acceptable salt thereof, for use in the treatment of neuroblastoma. The present invention also provides for the use of the compound of Formula I, or a pharmaceutically acceptable

salt thereof, for the manufacture of a medicament for the treatment of neuroblastoma. In one embodiment, the compound is provided as a free acid. In another embodiment, the compound of Formula I is provided as a base addition salt. In one preferred embodiment, the compound of Formula I is provided as a 2-methylpropan-2-ammonium salt. In still yet another embodiment, the compound of Formula I is provided as an ammonium salt.

The compound of Formula I, or pharmaceutically acceptable salt thereof, can be used in combination with the standard-of-care treatment for patients in need of treatment for neuroblastoma. The standard-of-care treatment can include one or more of the following: surgery or excision of all or a portion of the tumor, radiation therapy, stem cell transplant, administering a chemotherapeutic agents, differentiation agent, and immunotherapy.

Examples of additional chemotherapeutic agents that can be combined or administered with the compound of Formula I, or a pharmaceutically acceptable salt thereof include: alkylators (cyclophosphamide, temozolomide, and melphalan hydrochloride), platinum agents (carboplatin, cisplatin, and oxaliplatin), anthracyclines (doxorubicin hydrochloride), topoisomerase I inhibitors (irinotecan and topotecan), and vinca alkaloids (vincristine sulfate). Differentiation agents include isotretinoin (13-*cis*-retinoic acid), and immunotherapeutic agents include monoclonal antibodies such GD2 monoclonal antibodies (dinutuximab). The compound of Formula I, or a pharmaceutically acceptable salt thereof, and one or more additional chemotherapeutic agents, differentiation agents and/or immunotherapeutic agents can be administered simultaneously, separately, or sequentially to treat neuroblastoma.

The term "pharmaceutically acceptable salt" as used herein, refers to salts of the compound of Formula I. Examples of pharmaceutically acceptable salts and methods for their preparation can be found in, Stahl. P, et al., " Handbook of Pharmaceutical Salts: Properties, Selection and Use", 2nd Revised Edition, Wiley-VCH ,(2011) and Berge, S.,M., et al., "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, 1977, **66**(1), 1-19; Gould, P.L., "Salt selection for basic drugs", *International Journal of Pharmaceutics*, 1986, **33**: 201-217; and Bastin, R.J., *et al*. "Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities", *Organic Process Research and Development*, 2000, **4**(5) 427-435.

The compound of Formula I, or a pharmaceutically acceptable salt thereof, can be formulated for administration as part of a pharmaceutical composition. Preferred pharmaceutical compositions can be formulated as a tablet or capsule for oral administration, a solution for oral administration or an injectable solution. The tablet, capsule, or solution can include the compound of Formula I, or a pharmaceutically acceptable salt thereof, in an amount effective for treating neuroblastoma in a patient in need of treatment. More preferably, such compositions are for oral administration. As such, pharmaceutical compositions comprising the compound of Formula I, or a pharmaceutically acceptable salt thereof, can be in combination with one or more pharmaceutically acceptable additives. The term "pharmaceutically acceptable additive(s)" as used herein for the pharmaceutical compositions, refers to one or more of: carriers, diluents, and excipients that are compatible with the other additives of the composition or formulation and not deleterious to the patient. Examples of pharmaceutical compositions and processes for their preparation can be found in "Remington: The Science and Practice of Pharmacy", Loyd, V., *et al.* Eds., 22nd Ed., Mack Publishing Co., (2012). Non-limiting examples of pharmaceutically acceptable carriers, diluents, and excipients include the following: saline, water, starch, sugars, mannitol, and silica derivatives; binding agents such as carboxymethyl cellulose, alginates, gelatin, and polyvinyl-pyrrolidone; kaolin and bentonite; and polyethyl glycols.

"Effective amount" means the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof; or pharmaceutical composition containing the compound of Formula I, or pharmaceutically acceptable salt thereof, that will elicit the biological or medical response of or desired therapeutic effect on a tissue, system, animal, mammal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician. In certain embodiments, the effective amount refers to the amount of the compound of Formula I, or a pharmaceutically acceptable salt, when administered that is effective to slow, stop, or reverse the progression of neuroblastoma; or slow or stop the growth or proliferation of neuroblastoma cells in a patient.

The effective amount of the compound of Formula I, or a pharmaceutically acceptable salt thereof, actually administered that will elicit the biological or medical response of or desired therapeutic effect on a tissue, system or patient will be determined by a physician under the relevant circumstances, including the condition to be treated, the

chosen route of administration, the actual compound of the present invention administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms. Dosages per day normally fall within the range of about 0.1 to about 100 mg. In some instances, dosage levels below the lower limit of this range may be more than adequate, while in other cases still larger doses may be employed. Preferred dosages fall within the range of 1 to 80 mg; more preferably between 1 and 50 mg; still more preferably between 1 and 30 mg; still yet more preferably between 1 to 25 mg. The dosages can be administered once, twice, three times or more daily. In one embodiment, the compound of the present invention can be administered at a dosage of 15 mg or 25 mg per dose administered orally twice a day (BID).

As used herein, the term "patient" refers to a human or nonhuman mammal. More particularly, the term "patient" refers to a human.

The term "treating" (or "treat" or "treatment") refers to the process involving a slowing, interrupting, arresting, controlling, reducing, or reversing the progression or severity of a symptom, disorder, condition, or disease such as neuroblastoma

As used herein, the following terms have the meanings indicated: "ATCC" refers to American Type Culture collection; "BID" refers to twice a day dosing; "DMEM" refers to Dulbecco's Modified Eagle's Medium; "DNA" refers to deoxyribonucleic acid; "EMEM" refers to Eagles's Minimal Essential Medium; "F12" refers to Ham's F12 medium; "FBS" refers to Fetal Bovine Serum; "HBSS" refers to Hank's Balanced Salt Solution; "HSRRB" refers to Health Science Research Resources Bank; "JCRB" refers to Japanese Collection of Research Bioresources; "MEM" refers to Minimum Essential Medium; "NBL" refers to neuroblastoma; "NEAA" refers to Non-Essential Amino Acids; "PBS" refers to phosphate-buffered saline; "RPMI" refers to Roswell Park Memorial Institute; and "SCID" refers to severe combined immunodeficient mice.

The compound of Formula I and pharmaceutically acceptable salts thereof including the 2-methylpropan-2-ammonium and ammonia salts can be prepared according to the synthetic methods disclosed in US 9,637,474.

Biological Assays

Monolayer Anti-Proliferation Assays

One measure of potency of an Aurora A inhibitor is its ability to inhibit the proliferation of cancer cells in culture due to cell cycle arrest and mitotic catastrophe.

Anti-proliferative activity of Aurora A inhibitor in NBL cell lines may be indicative of clinical responsiveness to Aurora A inhibitors. The NBL tumor cell lines are recovered from frozen stocks and cultured for 1-2 passages in cell culture flasks. The NBL tumor cell lines include: CHP-212, GOTO, IMR-32, NB16, NH-6, SH-SY5Y, SK-N-AS, SK-N-DZ, SK-N-F1, SK-N-MC, SK-N-SH, and TGW detailed in Table 1.

Table 1

Cell line	Vendor	Catalog #	Lot. No	Histology	Complete medium
CHP-212	ATCC	CRL-2273	58063161	neuroblastoma	DMEM:F12(1:1)+10% FBS
IMR32	ATCC	CCL-127	59587034	neuroblastoma	EMEM + 10% FBS
SK-N-AS	ATCC	CRL-2137	58078525	neuroblastoma	DMEM + 0.1 mM NEAA + 10% FBS
NH-6	JCRB	JCRB0832	06262000	neuroblastoma with opsomyoclonus, truncal ataxia	alpha-MEM + 10% FBS
SK-N-DZ	ATCC	CRL-2149	3903996	brain, neuroblastoma	DMEM + 0.1 mM NEAA + 10% FBS
SK-N-FI	ATCC	CRL-2142	58078707	brain, neuroblastoma	DMEM + 0.1 mM NEAA + 10% FBS
SK-N-SH	ATCC	HTB-11	59257297	brain, neuroepithelioma	EMEM + 10% FBS
GOTO	HSRRB	JCRB0612		neuroblastoma	RPMI1640:MEM(1:1) + 10% FBS
NB16	RIKEN	RCB0478		neuroblastoma	RPMI1640 + 15% FBS
SH-SY5Y	ATCC	CRL-2266		neuroblastoma	MEM:F12(1:1) + 10% FBS
TGW	HSRRB	JCRB0618		neuroblastoma	MEM + 10% FBS
KELLY	Sigma	92110411		neuroblastoma	DMEM + 0.1 mM NEAA + 10% FBS

Anti-proliferative activity of an Aurora A inhibitor can be measured by CellTiter Glo® assay. Prior to treatment with the compound of Formula I, cells are plated in complete growth media into white walled clear bottom microtiter plates at a predetermined optimal density for each cell line. Sixteen hours after plating, the compound of Formula I is added. Two cell doubling times after compound addition, CellTiter-Glo® reagents are prepared according to the manufacturer's protocols, and added to each well. Plates are incubated at room temperature for 10 minutes then read

with a luminescence plate reader according to manufacturer's protocol for CellTiter-Glo® Luminescent Cell Viability Assay, Promega Catalog #G7571.

Anti-proliferative activity of an Aurora A inhibitor can also be measured by counting cells after treatment. For this assay, NBL cell lines SK-N-DZ, SK-N-F1, and KELLY are plated in complete growth media into black walled clear bottom microtiter plates at 5,000 cells per well. Sixteen hours after plating, the compound of Formula I is added for 72 hours. Cells are then fixed in 3.7% formaldehyde (Sigma # F-1268,) permeabilized with 0.1% Triton X-100 (Roche # 92522020) in PBS for 10 minutes then DNA is stained with Hoechst 33342 (Mol. Probes # H-21492) diluted 1:5000 in PBS. Stained plates are scanned with a CellInsight NXT® screening platform (Thermo Fischer) using the target activation bioapplication to quantitate nuclei per field, a measure of cells per well. For both assays, absolute EC_{50} values are reported from 10-point serial dilution curves of Formula I.

As illustrated in Table 2, pediatric NBL cell lines are highly sensitive to *in vitro* treatment with the compound of Formula I. This indicates that the compound of Formula I can be effective to inhibit the cell growth of a variety of neuroblastoma cell lines.

Table 2

Cell Line Name	Assay type	Biological Experimental Replicates	Technical Experimental Replicates	Mean (ABS† IC_{50})
CHP-212	CTG*	6		0.085
GOTO	CTG	4		20.000
IMR-32	CTG	4		0.016
NB16	CTG	4		0.035
NH-6	CTG	4		0.031
SH-SY5Y	CTG	4		0.047
SK-N-AS	CTG	4		0.823
SK-N-DZ	CTG	4		0.044
SK-N-DZ	Imaging‡		4	0.135
SK-N-FI	CTG	4		0.098
SK-N-FI	Imaging		4	0.290
SK-N-MC	CTG	4		0.873
SK-N-SH	CTG	4		0.078
TGW	CTG	4		0.154
KELLY	Imaging		4	0.396

*CTG refers to CellTiter-Glo® Luminescent Cell Viability Assay performed at HDBiosciences; † ABS means absolute; ‡Imaging = anti-proliferation assay measured by cell counts (nuclear staining)

Single Agent Efficacy in Neuroblastoma Xenograft Tumor Models

The efficacy of the compound of Formula I, or a pharmaceutically acceptable salt thereof, can be evaluated in *in vivo* mouse models of neuroblastoma. The compound of Formula I as 2-methyl-2-propanamine salt (34.5 mg/kg) can be administered orally to nude or C.B-17 SCID mice bearing cell-derived xenografts (CDX) using a 28 day BID dosing schedule. Tumor volume and body weight can be measured two times per week.

The following protocol can be used to measure reductions in tumor volume in response to an active pharmaceutical ingredient. Expand human NBL cancer cells in culture, harvest cycles and inject 5×10^6 cells in 200 µL of 1:1 solution of HBSS and Matrigel® subcutaneously into the right rear flank of female mice (20-24 g, Charles River Laboratories). The following cell line/ mouse strain combinations are used: SH-SY5Y (ATCC, #CRL-2226) in Athymic nude mice, KELLY (Sigma-#92110411) in C.B.-17 SCID mice, and IMR-32 (ATCC, #CCL-127) in C.B.-17 SCID mice.

Formulate the compound of Formula I as the 2-methyl-2-propanamine salt in 20% 2-hydroxypropyl-β-cyclodextrin in 25 mM phosphate buffer, pH 2 and dose orally at 34.5 mg/kg BID for 28 days. Measure body weight and tumor volume two times per week.

The compound of Formula I as the 2-methyl-2-propanamine salt is found to have % regression values as provided in Table 3.

Table 3

Evaluation of the Compound of Formula I as the 2-Methyl-2-Propanamine Salt in Neuroblastoma Xenograft Models

Model	Xenograft Type	N	% Regression (-) at End of Treatment	p-value	% Bodyweight Change
KELLY	CDX*	5	-59.4	<0.001	-5.3
SH-SY5Y	CDX	5	-78.8	<0.001	-1.1
IMR-32	CDX	4	-94.3	<0.001	4.7

CDX refers to Cell Derived Xenograft Type.
N refers to # of replicates.

These results indicate that the compound of Formula I as the 2-methyl-2-propanamine salt demonstrates significant anti-tumor activity in human NBL xenograft models. The compound of Formula I as the 2-methyl-2-propanamine salt is effective as a single agent in 100% (3/3) of the pediatric NBL *in vivo* mouse models tested, with results ranging from stable disease to complete response.

What is Claimed is:

1. A method of treating neuroblastoma in a patient comprising administering to a patient in need of such treatment an effective amount of a compound which is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 wherein the compound is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid.

3. The method according to claim 1 wherein the compound is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid : 2-methylpropan-2-amine (1:1) salt.

4. The method according to claim 1 wherein the compound is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid : amine (1:1) salt.

5. A method of treating neuroblastoma in a patient comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a compound which is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

6. The method of claim 5 wherein the composition comprises a compound which is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-

methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid.

7. The method of claim 5 wherein the composition comprises a compound which is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid : 2-methylpropan-2-amine (1:1) salt.

8. The method of claim 5 wherein the composition comprises a compound which is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid : amine (1:1) salt.

9. A compound which is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, for use in the treatment of neuroblastoma.

10. The compound for use according to claim 9 which is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid.

11. The compound for use according to claim 9 which is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid : 2-methylpropan-2-amine (1:1) salt.

12. The compound according to claim 9 which is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid : amine (1:1).

13. Use of a compound, which is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, for manufacture of a medicament for the treatment of neuroblastoma.

14. The use according to claim 13 wherein the compound is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid.

15. The use according to claim 13 wherein the compound is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid 2-methylpropan-2-amine (1:1) salt.

16. The use according to claim 13 wherein the compound is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid amine (1:1) salt.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2019/062718

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K31/445 A61P35/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, BIOSIS, EMBASE, SCISEARCH, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	STEVEN G. DUBOIS ET AL: "Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.", JOURNAL OF CLINICAL ONCOLOGY, vol. 34, no. 12, 20 April 2016 (2016-04-20), pages 1368-1375, XP055668757, US ISSN: 0732-183X, DOI: 10.1200/JCO.2015.65.4889 abstract page 1368, column 2, paragraph 1 - page 1369, column 1, paragraph 2 page 1372, column 2, paragraph 3-4 ----- -/--	1-16

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
14 February 2020	02/03/2020

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Cielen, Elsie

2

Form PCT/ISA/210 (second sheet) (April 2005)

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	H Sootome ET AL: "433 Genomic predictors of therapeutic sensitivity to TAS-119, a selective inhibitor of Aurora-A kinase Abstract Number: 433.", European Journal of Cancer, Vol. 50, Supp. SUPPL. 6, 1 November 2014 (2014-11-01), pages 142-143, XP055668614, Retrieved from the Internet: URL:https://www.ejcancer.com/article/S0959-8049(14)70559-3/pdf [retrieved on 2020-02-13] the whole document	1-16
Y	XUEQIAN GONG ET AL: "Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene", CANCER DISCOVERY, vol. 9, no. 2, 29 October 2018 (2018-10-29), pages 248-263, XP055668711, US ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-18-0469 abstract page 253; figure 2 page 258, column 2, paragraph 2	1-16
Y	CHONGHAILE T N: "Illuminating Aurora dependencies", SCIENCE TRANSLATIONAL MEDICINE 20181114 AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE USA, vol. 10, no. 468, 14 November 2018 (2018-11-14), XP002797677, ISSN: 1946-6234 page 2, paragraph 2	1-16
Y	WO 2016/077161 A1 (LILLY CO ELI [US]) 19 May 2016 (2016-05-19) cited in the application pages 16-18; examples 1-3 page 23, lines 15-21 page 24, lines 17-20 page 31, lines 3-6 claims 1-3, 5, 6	1-16

-/--

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	Anonymous: "History of Changes for Study: NCT04106219 A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma", ClinicalTrials.gov archive, 25 September 2019 (2019-09-25), pages 1-6, XP55668553, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/history/NCT04106219?V_1=View#StudyPageTop [retrieved on 2020-02-13] Study description; page 2 Arms and interventions; pages 2-3 -----	1-16

2

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2019/062718

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2016077161 A1	19-05-2016	AR 102463 A1	01-03-2017
		AU 2015347043 A1	04-05-2017
		BR 112017007239 A2	19-12-2017
		CA 2963473 A1	19-05-2016
		CL 2017001209 A1	12-01-2018
		CN 107108567 A	29-08-2017
		CR 20170158 A	21-06-2017
		DK 3218366 T3	01-04-2019
		DO P2017000111 A	15-06-2017
		EA 201790838 A1	29-12-2017
		EP 3218366 A1	20-09-2017
		EP 3473619 A1	24-04-2019
		ES 2716732 T3	14-06-2019
		HR P20190324 T1	19-04-2019
		HU E043759 T2	30-09-2019
		IL 251406 A	29-08-2019
		JP 6159029 B2	05-07-2017
		JP 2016539942 A	22-12-2016
		KR 20170066623 A	14-06-2017
		LT 3218366 T	10-04-2019
		NZ 730771 A	27-07-2018
		PE 20170898 A1	12-07-2017
		PH 12017500881 A1	06-11-2017
		PL 3218366 T3	28-06-2019
		PT 3218366 T	01-04-2019
		SG 11201703394R A	30-05-2017
		SI 3218366 T1	28-02-2019
		SV 2017005418 A	09-10-2018
		TN 2017000116 A1	04-07-2018
		TR 201902686 T4	21-03-2019
		TW 201629038 A	16-08-2016
		UA 117983 C2	25-10-2018
		US 2016137628 A1	19-05-2016
		US 2017119751 A1	04-05-2017
		WO 2016077161 A1	19-05-2016
		ZA 201702199 B	19-12-2018